TARS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Tarsus Pharmaceuticals's Average Total Inventories for the three months ended in Dec. 2024 was $2.7 Mil. Tarsus Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2024 was $4.9 Mil. Hence, Tarsus Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 was 50.63.
The historical rank and industry rank for Tarsus Pharmaceuticals's Days Inventory or its related term are showing as below:
During the past 7 years, Tarsus Pharmaceuticals's highest Days Inventory was 711.90. The lowest was 81.49. And the median was 396.70.
Tarsus Pharmaceuticals's Days Inventory declined from Dec. 2023 (117.14) to Dec. 2024 (50.63).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year. Tarsus Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2024 was 1.80.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Tarsus Pharmaceuticals's Inventory-to-Revenue for the three months ended in Dec. 2024 was 0.04.
The historical data trend for Tarsus Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Days Inventory | Get a 7-Day Free Trial | - | - | - | 711.90 | 81.49 |
Tarsus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
117.14 | 197.04 | 94.64 | 70.94 | 50.63 |
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Tarsus Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as
Days Inventory (A: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2023 ) | + | Total Inventories (A: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2024 ) | * | Days in Period |
= | ( (3.107 | + | 2.62) | / | 2 ) | / | 12.826 | * | 365 |
= | 2.8635 | / | 12.826 | * | 365 | ||||
= | 81.49 |
Tarsus Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:
Days Inventory (Q: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2024 ) | + | Total Inventories (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (2.846 | + | 2.62) | / | 2 ) | / | 4.926 | * | 365 / 4 |
= | 2.733 | / | 4.926 | * | 365 / 4 | ||||
= | 50.63 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (NAS:TARS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Tarsus Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 4.926 | / | 2.733 | |
= | 1.80 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Tarsus Pharmaceuticals's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 2.733 | / | 66.408 | |
= | 0.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Tarsus Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Dianne C. Whitfield | officer: Chief Human Resources Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bryan Wahl | officer: General Counsel | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Seshadri Neervannan | officer: Chief Operating Officer | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Bobak R. Azamian | director, 10 percent owner, officer: President and CEO | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Aziz Mottiwala | officer: Chief Commercial Officer | 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401 |
Jeffrey S Farrow | officer: See Remarks | TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Link William J Phd | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Jose M. Trevejo | officer: Chief Medical Officer | C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Andrew D. Goldberg | director | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Elizabeth Yeu Lin | director | 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630 |
Leonard M. Greenstein | officer: Chief Financial Officer | 24562 BELGREEN PLACE, LAKE FOREST CA 92630 |
Mark J. Holdbrook | officer: V.P., Clinical Affairs | 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE CA 92618 |
Scott W Morrison | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
Vivo Capital Fund Ix, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Michael Ackermann | director, 10 percent owner | 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
From GuruFocus
By GuruFocus News • 01-31-2025
By GlobeNewswire • 03-13-2025
By GuruFocus News • 02-26-2025
By Marketwired • 03-13-2025
By Marketwired • 01-30-2025
By GuruFocus News • 11-15-2024
By GuruFocus News • 02-25-2025
By Marketwired • 11-13-2024
By GuruFocus News • 01-30-2025
By GuruFocus News • 02-26-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.